TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05162118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with Nivolumab
Description: Intratumoral injection of VG161 on day 1 only or day 1 through 3, in combination of Nivolumab intravenous injection only, Once every 2 weeks, 3 mg/kg each time.
Study: NCT06362408

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: Older patients who have used dexmedetomidine(safe use range: 0.2\~1.0 μg/(kg·h)) for anesthesia induction or maintenance during surgery were classified as the DEX group. On the contrary, patients who did not use dexmedetomidine throughout the entire anesthesia process were identified as the Non-DEX group.
Study: NCT05421858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosmanogepix
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosmanogepix
Description: Oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caspofungin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Fluconazole oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for caspofungin (IV infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for fluconazole (oral capsule)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo for fosmanogepix (IV infusion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo for fosmanogepix (oral tablet)
Study: NCT05471843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Administered orally
Study: NCT06452836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green color exposure
Description: Patients will wear green colored glasses before and during the surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red color exposure
Description: Patients will wear red colored glasses before and during the surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue color exposure
Description: Patients will wear blue colored glasses before and during the surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: Patients will wear translucent glasses before and during the surgery.
Study: NCT06255496

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra Hemostasis Analyzer with the QStat Cartridge
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study: NCT06572384

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be administered.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT06573281

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational RSV vaccine 1
Description: Investigational RSV vaccine 1 administered intramuscularly on Day 1 and Day 30.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational RSV vaccine 2
Description: Investigational RSV vaccine 2 administered intramuscularly on Day 1 and Day 30.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational RSV vaccine 3
Description: Investigational RSV vaccine 3 administered intramuscularly on Day 1 and Day 30.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational RSV vaccine 4
Description: Investigational RSV vaccine 4 administered intramuscularly on Day 1 and Day 30.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational RSV vaccine 5
Description: Investigational RSV vaccine 5 administered intramuscularly on Day 1 and Day 30.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational RSV vaccine 6
Description: Investigational RSV vaccine 6 administered intramuscularly on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intramuscularly on Day 1 and Day 30 and for RSV_Group F placebo administered only on Day 30.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered intramuscularly on Day 1 and Day 30 and for RSV_Group F placebo administered only on Day 30.
Study: NCT06102460

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein protein
Description: 40 grams of casein protein powder mixed with 8-10 fl. oz. of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: a-lactalbumin protein
Description: 40 grams of a-lactalbumin protein powder mixed with 8-10 fl. oz. of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate
Description: 40 grams of a carbohydrate powder mixed with 8-10 fl. oz. of water.
Study: NCT06574555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: The outcome of patient n in each sequence will determine the dose to be allocated patient n+1.~Successive doses will be determined with the up-and-down k-in-row design method for ED90 determination:~* Failure: the dose should be increased in one level (+0.02 µg/kg) after failure to respond (arterial hypotension);~* Success: decrease in one level (-0.02 µg/kg) upon successful response (no arterial hypotension), but only after observing at least k-consecutive positive responses at the same dose (in this case, k=7); otherwise, remain at the same dose.~This will be done until each sequence completes n=30.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: The outcome of patient n in each sequence will determine the dose to be allocated patient n+1.~Successive doses will be determined with the up-and-down k-in-row design method for ED90 determination:~* Failure: the dose should be increased in one level (+0.02 µg/kg) after failure to respond (arterial hypotension);~* Success: decrease in one level (-0.02 µg/kg) upon successful response (no arterial hypotension), but only after observing at least k-consecutive positive responses at the same dose (in this case, k=7); otherwise, remain at the same dose.~This will be done until each sequence completes n=30.
Study: NCT06209684

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium
Description: Spinal stabilization using titanium screws and rods

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbofix
Description: Spinal stabilization using CarboFix screws and rods
Study: NCT06350630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Oral Tablet
Description: Active hydroxychloroquine once daily by oral route at 6.5 mg/kg of ideal weight/day, with maximal dose of 400mg/day for 3 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: placebo once daily by oral route (no active drug - same dosage as hydroxychloroquine )
Study: NCT04657289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals~Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals~Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Port Delivery System with Ranibizumab
Description: Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals~Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Port Delivery System with Ranibizumab
Description: Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals~Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals
Study: NCT05170204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Participants will receive oral alectinib twice daily with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Participants will receive oral entrectinib once daily, with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Participants will receive IV durvalumab every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Participants will receive IV durvalumab every 4 weeks.
Study: NCT05878769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astegolimab
Description: Participants will receive SC astegolimab Q2W
Study: NCT04715893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ostomy belt
Description: Stealth ostomy belt continuous for eight weeks
Study: NCT05835986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7507062
Description: RO7507062 solution for injection will be administered SC as specified in each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7507062
Description: RO7507062 solution for injection will be administered SC as specified in each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab solution for infusion will be administered intravenously at 8 milligram per kilogram (mg/kg) for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab solution for infusion will be administered intravenously at 8 milligram per kilogram (mg/kg) for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
Study: NCT05180552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEALiX is an alternative restraint patient safety device
Description: The HEALiX is a rigid, spiral, exoskeleton-like device made of lightweight stainless steel (Austenitic SAE 316 or equivalent) that comes in various sizes to fit different arm lengths circumference of the patient's bicep. After appropriate measuring and following the fit guide, the HEALiX is placed on the patient's arm so that the hand rests on a soft, padded hand cradle. The trajectory of the end hand cradle is at a 30-degree upward angle to prevent peripheral dependent edema. This hand cradle is surrounded by foam to provide increased support for the patient and also to protect the medical team from any injury. A wrist bracelet (wrist assist) goes around the patient's wrist and prevents the patient from removing the device. The spiral exoskeleton holds the arm in a neutral position with contact points with the patient's skin at the upper deltoid region only.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: soft wrist restraints
Description: Soft wrist restraints are padded cloth restraints that are worn by patients on wrist and secured to bed frame.
Study: NCT02809196

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 1: Tailored SMS program implicating friend and mother

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2: Standardized SMS program implicating friend and mother

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 3: Tailored SMS program implicating friend, not mother

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4: Standardized SMS program implicating friend, not mother

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 5: Tailored SMS program implicating mother, not friend

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 6: Standardized SMS program implicating mother, not friend

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 7: Tailored SMS program not implicating mother or friend

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 8: Standardized SMS program not implicating mother or friend

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 9: No SMS program
Study: NCT05467163

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular pacemaker implantation
Description: Implantation of permanent pacemaker with biventricular stimulation with or without defibrillator lead placement using standard techniques. The right ventricle lead will be positioned in the RV apex or septum, while the left ventricle lead will be delivered to the most appropriate coronary sinus tributary, preferably posterolateral or lateral vein.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conduction system pacing device implantation
Description: Left bundle branch pacing (LBBP) will be the preferred pacing technique. In brief, after localizing the His bundle area the LBBP lead will be positioned approximately 1-1.5 cm distal to the His bundle position in the right ventricular septum. Before screwing the lead deep into the interventricular septum, the suitable position will be confirmed by fluoroscopic signs and adequate paced QSR morphology. Given that the pacing parameters with LBBP are typically low and stable, backup RV lead will not be mandatory. If LBBP will be unobtainable, His bundle pacing (HBP) implantation will be attempted. His bundle potential mapping will be performed with the use of the electrophysiological system and under fluoroscopic guidance. Distal HB potential with a large ventricular signal and a small atrial signal will be targeted before the pacing lead will be screwed into position. Backup RV lead will be mandatory for all patients receiving HBP devices.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AV node ablation
Description: Atrioventricular node ablation (AVNA) will be performed following pacemaker implantation (preferably during the same hospitalization). After femoral vein access will be obtained, the ablation catheter will be positioned to the presumed area of the AV node in the mid-septum under fluoroscopy. The location will be optimized according to the intracardiac electrograms. Ablation will be performed in a temperature-controlled mode. Successful AVNA will be recognized with an abrupt drop of heart rate to 40 bpm and will continue for 60 seconds thereafter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AV node ablation
Description: Atrioventricular node ablation (AVNA) will be performed following pacemaker implantation (preferably during the same hospitalization). After femoral vein access will be obtained, the ablation catheter will be positioned to the presumed area of the AV node in the mid-septum under fluoroscopy. The location will be optimized according to the intracardiac electrograms. Ablation will be performed in a temperature-controlled mode. Successful AVNA will be recognized with an abrupt drop of heart rate to 40 bpm and will continue for 60 seconds thereafter.
Study: NCT04646603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG-001
Description: Subjects will receive subcutaneous MRG-001 injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive subcutaneous placebo injections.
Study: NCT04857983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Subjects will be assigned to take memantine or placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
Study: NCT06102460

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Zero calorie, placebo powder mixed with 8-10 fl. oz. of water.
Study: NCT05336227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exergaming
Description: The VR intervention will include home-based exercise using the Oculus Quest, a heart rate monitor (Polar OH1), BP cuff, and mobile application. The games will include rhythmic movements to music and sport/recreation activities that elicit high energy expenditure. Participants will be instructed to reach 150 minutes per week of moderate-exercise in week 1 and maintain this volume across the 12-week intervention. The intervention will include behavioral, physical education coaching through videoconference, which we refer to as Tele-PE. Tele-PE will aim to enhance adherence, provide basic exercise knowledge, and increase mastery playing the games. Calls will last 15 minutes, and be provided weekly in month 1, bi-weekly in month 2, and one call at the end of month 3.
Study: NCT04296630

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social media message #1
Description: Social media message promoting colorectal cancer screening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social media message #2
Description: A different social media message promoting colorectal cancer screening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social media message #3
Description: A different social media message promoting colorectal cancer screening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social Media Message #4
Description: A different social media message promoting colorectal cancer screening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Social Media Message
Description: Tailored social media messages promoting colorectal cancer screening.
Study: NCT04857983

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be assigned to take memantine or placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
Study: NCT05724524

Intervention type: OTHER
Intervention: Stool sample collection
Description: 50mg stool sample taken for protein extraction

Intervention type: OTHER
Intervention: Stool sample collection
Description: 50mg stool sample taken for protein extraction

Intervention type: OTHER
Intervention: Blood sample collection
Description: Venous blood sample taken for analysis of serum and plasma

Intervention type: OTHER
Intervention: Blood sample collection
Description: Venous blood sample taken for analysis of serum and plasma
Study: NCT04988607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: osimertinib plus bevacizumab arm is dosed at osimertinib 80 mg orally once every day combined with bevacizumab 15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: osimertinib plus bevacizumab arm is dosed at osimertinib 80 mg orally once every day combined with bevacizumab 15mg/kg by intravenous drip infusion on day 1 of a

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Osimertinib is dosed orally at 80 mg once per day
Study: NCT04855487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-patient dyadic storytelling intervention
Description: During the 5-week online intervention, adolescents/young adults with cancer will create their stories following the guiding questions and online meetings with nursing research staff. The target audience of their stories will be their primary nurses. This online dyadic storytelling intervention is designed to promote in-depth self-reflection and meaningful and therapeutic relationships within bedside nurses. The intervention is designed following the Story Theory and Pennebaker's Expressive Writing paradigm.
Study: NCT05698654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting-mimicking diet (FMD)
Description: The subjects will be instructed to follow their usual diet plan, except for 5 days when they eat the foods in the FMD box.The fasting-mimicking diet consists of a blend of 100% plant based nutrients generally regarded as safe. The formulation of these products is based on studies carried out at the Longevity Institute of the University of Southern California and his collaborators over several decades of studies.~This food plan provides for the replacement of the normal diet with the organic plant products contained in the fasting-mimicking diet for five consecutive days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Longevity Diet (LD) + Fasting-mimicking Diet (FMD)
Description: The subjects will be instructed to follow their longevity diet plan, except for 5 days when they eat the foods in the FMD box, based on the following guidelines:~vegan based diet with the addition of low mercuryfish 2-3 times a week; protein content should be 0.7-0.8 grams per kilogram of ideal weight per day (most of the protein coming from whole cereals,vegetables, legumes and tree nuts only part from fish); monounsaturated and polyunsaturated fats are predominant and very low amounts of saturated and trans-fats are allowed; complex Carbohydrates from vegetables, whole grains and legumes; addition of vitamins, minerals and Omega3 fats; food selected between the traditional food consumed by ancestry; time-restricted feeding: all food must be consumed within 12 hours each day. for those who are overweight or are nearly overweight (BMI \>25 kg/m2), either lunch or dinner will be substituted with a low calorie, low sugar snack (approximately 100 kcal: salad, nuts, fruit, etc.).
Study: NCT05631990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-209
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-209-1A
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-209-1B
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-209-1C
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-209 placebo
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-209 placebo
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-209 placebo
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-209-1 placebo
Description: PO, Once daily(QD), 8weeks
Study: NCT04921696

Intervention type: OTHER
Intervention: RBC transfusion
Description: RBC was transfused to the infants.

Intervention type: OTHER
Intervention: no-RBC transfusion
Description: RBC was not transfused to the infants.